Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CTNM · as of Sep 30, 2025
Ownership Breakdown
63
Institutional Holders
▼ 8 vs Q2
$205.68M
Total Inst. Value
▲ $150.29M vs Q2
37.39M
Shares Outstanding
freeFloat 73.81%
17.51M
13F Shares Held
▲ 3.62M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CTNM largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 2.12M | 8.19% | 8.19% | $24.93B | Nov 14, 2025 | NEW |
JOHNSON & JOHNSON pharmaceutical preparations | 1.98M | 7.64% | 7.64% | $23.26B | Mar 18, 2026 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.72M | 6.64% | 6.64% | $20.21B | Nov 14, 2025 | — held |
FRANKLIN RESOURCES INC pharmaceutical preparations | 1.66M | 6.39% | 6.39% | $19.45B | Nov 13, 2025 | ▼ 43.3K |
VANGUARD GROUP INC pharmaceutical preparations | 964.2K | 3.72% | 3.72% | $11.33B | Nov 7, 2025 | ▲ 220.2K |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 951.3K | 3.67% | 3.67% | $11.18B | Nov 14, 2025 | NEW |
FMR LLC pharmaceutical preparations | 814.9K | 3.15% | 3.15% | $9.57B | Nov 13, 2025 | ▼ 28.3K |
SECTORAL ASSET MANAGEMENT INC pharmaceutical preparations | 800.8K | 3.09% | 3.09% | $9.41B | Nov 14, 2025 | — held |
PERCEPTIVE ADVISORS LLC pharmaceutical preparations | 714.6K | 2.76% | 2.76% | $8.40B | Nov 14, 2025 | ▲ 15.1K |
HHLR ADVISORS, LTD. pharmaceutical preparations | 669.3K | 2.58% | 2.58% | $7.86B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
17
Increased
+1.68M shares9
New Positions
first time holders13
Decreased
−715.3K shares0
Sold Out
fully exitedNet shares change (top 50)
+962.3K
+1.68M / −715.3K
Net new holders
+13
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CTNM insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
4
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lorrain Daniel S. Chief Scientific Officer | Jun 1, 2026 | Sale | 4,170 | $13.16 | $54.9K | 139.4K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | May 1, 2026 | Sale | 3,870 | $13.06 | $50.5K | 143.8K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | May 1, 2026 | Sale | 300 | $13.84 | $4.2K | 143.5K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Apr 6, 2026 | Sale | 4,170 | $13.43 | $56.0K | 147.7K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Mar 2, 2026 | Sale | 4,170 | $15.01 | $62.6K | 151.9K | Form 4 ↗ |
Watkins Tim CMO & Head of Development | Mar 2, 2026 | Sale | 3,611 | $15.02 | $54.2K | 0 | Form 4 ↗ |
Stengone Carmine N. CEO and President | Feb 24, 2026 | Sale | 4,400 | $16.02 | $70.5K | 15.0K | Form 4 ↗ |
Stengone Carmine N. CEO and President | Feb 25, 2026 | Sale | 2,700 | $16.02 | $43.2K | 15.0K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Feb 25, 2026 | Sale | 3,824 | $16.01 | $61.2K | 156.1K | Form 4 ↗ |
Lorrain Daniel S. Chief Scientific Officer | Feb 24, 2026 | Sale | 4,300 | $16.03 | $68.9K | 156.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is primarily owned by institutional investors, who hold approximately 46.8% of total shares outstanding. Company insiders own approximately 26.19%, while retail and public investors account for the remaining 26.99%.
The largest institutional shareholder of Contineum Therapeutics, Inc. Class A Common Stock is RA CAPITAL MANAGEMENT, L.P., holding approximately 2.12 million shares — equal to 8.19% of outstanding shares — as of September 30, 2025.
A total of 63 institutional investors currently hold CTNM stock, with a combined institutional value of approximately $205,683,000 as of the most recent 13F filing period.
Frequently asked questions
CTNM ownershipContineum Therapeutics, Inc. Class A Common Stock (CTNM) is primarily owned by institutional investors, who hold approximately 46.8% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 8.19% stake. Company insiders hold 26.19%. Data sourced from SEC Form 13F as of September 30, 2025.